PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18330707-6	2008	siRNA-mediated inhibition of ectopic ISG12a protein expression prevented the sensitization to etoposide-induced apoptosis and also decreased the ability of IFN-beta pretreatment to sensitize cells to etoposide, thereby demonstrating a role for ISG12a in this process.	Etoposide	200-209	interferon beta 1	Homo sapiens	156-164	
19267105-1	2008	Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide.	Etoposide	149-158	interferon beta 1	Homo sapiens	0-15	
9506459-4	1998	Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs.	Etoposide	86-95	interferon beta 1	Homo sapiens	39-47	
22595795-9	2012	However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine).	Etoposide	189-198	interferon beta 1	Homo sapiens	99-107	
7762995-0	1995	IFN-beta inhibition of etoposide resistance acquisition in vitro: studies using a human glioblastoma cell line.	Etoposide	23-32	interferon beta 1	Homo sapiens	0-8	
7762995-1	1995	The inhibition by IFN-beta of acquired resistance to the epipodophillotoxin etoposide was studied using a human glioblastoma cell line, T98G.	Etoposide	76-85	interferon beta 1	Homo sapiens	18-26	
7762995-8	1995	The present results show that resistant cells have less topoisomerase II than sensitive cells, suggesting that IFN-beta inhibits the acquisition of resistance to etoposide by suppressing the alteration in topoisomerase II.	Etoposide	162-171	interferon beta 1	Homo sapiens	111-119	
7762995-9	1995	The inhibition of acquired resistance to etoposide by IFN-beta suggests that continuous and repeated chemotherapy for glioblastoma and other malignant tumors may be clinically advantageous.	Etoposide	41-50	interferon beta 1	Homo sapiens	54-62	
3866799-5	1985	The combinations VP-16-213/IFN-beta and cis-platinum/IFN-beta produced the most pronounced synergistic effects.	Etoposide	17-22	interferon beta 1	Homo sapiens	27-35	
22396773-9	2012	Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression.	Etoposide	72-81	interferon beta 1	Homo sapiens	149-157